CAMBRIDGE, MA – March 21, 2024 – HiFiBiO Therapeutics, a leading clinical stage global biotechnology company committed to advancing patient outcomes through single-cell precision, announced today its participation in the AACR 2024 meeting, scheduled to take place April 5-10, 2024, in San Diego, CA.
On Tuesday, April 9th, Dr. Jack Russella-Pollard will present an innovative Artificial Intelligence/Machine Learning (AI/ML)-guided approach designed to seamlessly integrate single-cell data across platforms at scale. The next day, Dr. Jinping Gan will showcase PK/PD models that integrate drug properties and tumor growth characteristics, providing biologically insightful stimulations.
By harnessing these cutting-edge technologies and tools, HiFiBiO Therapeutics is steering the development of its drug candidates, including three antibodies currently undergoing Phase 1 evaluation: a first-in-class TNFR2 agonist (HFB200301, NCT05238883), a next-generation OX40 agonist (HFB301001, NCT05229601), and a novel BTLA antagonist (HFB200603, NCT05789069).
These presentations underscore HiFiBiO Therapeutics’ unwavering commitment to innovation and its relentless pursuit of novel therapeutic solutions to address unmet medical needs.
Details on the poster presentations are as follows:
Abstract Number: 6202
Title: Integrating public single-cell transcriptomics and patient profiles to guide clinical development
Presenter: Jack Russella-Pollard, Ph.D., Executive Director, Translational Data Science
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Session Title: Integrative Cancer Science
Session Date and Time: Tuesday Apr 9, 2024, 1:30 PM – 5:00 PM
Location: Poster Section 36
Poster Board Number: 5
Abstract Number: 7176
Title: Optimization of T cell co-stimulatory agonists: A semi-mechanistic PKPD model integrating drug properties and tumor-immune interactions
Presenter: Jinping Gan, Ph.D., Vice President, Global Head of Research
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacology and Pharmacogenetics
Session Date and Time: Wednesday Apr 10, 2024, 9:00 AM – 12:30 PM
Location: Poster Section 24
Poster Board Number: 17
The full abstracts can be viewed on the AACR website.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage global biotech driving a robust clinical pipeline of transformative immunotherapies targeting cancer and autoimmune diseases. HiFiBiO achieves an unprecedented understanding of immune modulation in human diseases by pioneering a unique high-resolution translational platform, Drug Intelligence Science (DIS®), which combines unique single-cell capabilities with AI/ML approaches. Using patient samples, DIS® enables the discovery of novel targets, effective antibody drugs, and predictive biomarkers to enhance the probability of success for immunotherapies. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized as one of the 2023 Fierce 15 biotech companies. For additional information, please visit www.hifibio.com
HiFiBiO Therapeutics and the HiFiBiO Therapeutics logo are trademarks of HiFiBiO and its affiliates.